POLYPHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
POLYPHARMA
Largest movements
- Cash -€11,377
down €11,377 (-44.6%), from €25,492 to €14,115
mainly Net result for the year (-€8,671) and Receivables within one year (-€2,706)
- Receivables within one year +€2,706
up €2,706 (+102.7%), from €2,634 to €5,339
of which Other amounts receivable: +€3,069
- Profit (loss) carried forward -€8,671
down €8,671, from €7,926 to -€746
- Gross operating margin -€473
down €473 (-5.8%), from -€8,107 to -€8,580
- Other operating charges -€335
down €335 (-86.4%), from €387 to €53
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €28,826 | €20,154 | -€8,671 | -30.1% |
| Fixed assets | 21/28 | €50 | €50 | = | 0.0% |
| Financial fixed assets | 28 | €50 | €50 | = | 0.0% |
| Current assets | 29/58 | €28,776 | €20,104 | -€8,671 | -30.1% |
| Amounts receivable within one year | 40/41 | €2,634 | €5,339 | +€2,706 | +102.7% |
| Trade receivables | 40 | €363 | - | -€363 | |
| Other amounts receivable | 41 | €2,271 | €5,339 | +€3,069 | +135.2% |
| Cash at bank and in hand | 54/58 | €25,492 | €14,115 | -€11,377 | -44.6% |
| Deferred charges and accrued income | 490/1 | €650 | €650 | = | 0.0% |
| Total equity and liabilities | 10/49 | €28,826 | €20,154 | -€8,671 | -30.1% |
| Equity | 10/15 | €28,826 | €20,154 | -€8,671 | -30.1% |
| Contributions | 10/11 | €19,000 | €19,000 | = | 0.0% |
| Reserves | 13 | €1,900 | €1,900 | = | 0.0% |
| Non-distributable reserves | 130/1 | €1,900 | €1,900 | = | 0.0% |
| Reserves not available under the articles | 1311 | €1,900 | €1,900 | = | 0.0% |
| Profit (loss) carried forward | 14 | €7,926 | -€746 | -€8,671 | |
| Other operating charges | 640/8 | €387 | €53 | -€335 | -86.4% |
| Gross operating margin | 9900 | -€8,107 | -€8,580 | -€473 | -5.8% |
| Operating profit (loss) | 9901 | -€8,494 | -€8,632 | -€138 | -1.6% |
| Financial charges | 65/66B | €58 | €39 | -€19 | -32.2% |
| Recurring financial charges | 65 | €58 | €39 | -€19 | -32.2% |
| Profit (loss) for the period before taxes | 9903 | -€8,551 | -€8,671 | -€120 | -1.4% |
| Profit (loss) for the period | 9904 | -€8,551 | -€8,671 | -€120 | -1.4% |
| Profit (loss) for the period to be appropriated | 9905 | -€8,551 | -€8,671 | -€120 | -1.4% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 28 September 2026 via checked.be.